Schrodinger SDGR Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Gross Profit by Business | ||||||
| Drug Discovery | $6.29M+251% | —— | -$1.71M+69.9% | -$1.36M-144% | -$4.17M+36.3% | |
| Software | $23.26M-34.1% | $55.94M-15.7% | $29.75M+27.1% | $27.52M-2.6% | $35.29M+38.7% | |
| Total revenues by Product | ||||||
| Hosted software | $12.08M+11.1% | $11.54M+3.2% | $11.59M+31.4% | $11.13M+37.6% | $10.87M+51.5% | |
| On-premise software | $14.18M-44.2% | $44.35M-19.9% | $15.93M+30.0% | $15.74M-16.1% | $25.42M+44.3% | |
| Professional services | $2.64M+40.2% | $3.8M+64.0% | $1.59M-22.0% | $2.38M-12.4% | $1.88M-31.0% | |
| Software maintenance | $6.66M-2.0% | $6.89M+17.1% | $6.83M+20.6% | $6.78M+16.1% | $6.8M+15.3% | |
| Software products and services | $35.56M-20.9% | $69.28M-13.0% | $40.86M+28.1% | $40.54M+14.5% | $44.97M+34.6% | |
| Drug discovery services revenue from contracts with customers by Product | ||||||
| Drug Discovery Services | $11.7M+105% | $17.58M+116% | $13.01M+362% | $13.94M+21.2% | $5.7M+112% | |
| Receivable, after allowance for credit loss, current by Product | ||||||
| Oncology, Neurology, and Immunology Product | $0— | $0— | $0— | $0— | $0— | |
| Software contribution | $0— | $0-100% | $0— | $0— | $0— | |
| Restricted cash (includes related party amounts of $0 and $72, respectively) by Product | ||||||
| Contribution | $0— | $72K— | —— | —— | —— | |
| Software contribution | $0-100% | $0-100% | $2.69M— | $5.38M— | $4.83M— | |
| Total revenues by Geography | ||||||
| APAC | $20.17M-12.6% | $22.8M-49.9% | $15.72M+206% | $13.56M+55.7% | $23.08M+221% | |
| EMEA | $6.67M+9.9% | $6.38M+1.1% | $6.76M+27.9% | $6.97M-10.7% | $6.07M+10.4% | |
| Rest of World | $333K-54.4% | $141K-43.6% | $515K+112% | $175K+44.6% | $731K+21.0% | |
| United States | $31.41M+5.9% | $57.92M+59.8% | $31.33M+27.2% | $34.05M+10.9% | $29.66M+27.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Schrodinger break its business down?
- Schrodinger (SDGR) reports gross profit by business across 2 parts — Drug Discovery and Software. Each is extracted from the segment footnotes and tracked over time.
- Where does Schrodinger's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Schrodinger's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
